Owlstone Medical Selected to Participate at Upcoming Cavendish Global Health Impact Forum

Published on 05 Dec 16, under Press releases

Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences.

Cambridge, UK, December 5th — Owlstone Medical, a diagnostics company developing a breathalyzer for disease , announced today it has been selected to present at the ninth Cavendish Global Health Impact Forum taking place February 6-8, 2017 in San Diego, California. The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Owlstone Medical’s breath analysis technology positions them to make a major contribution in clinical diagnostics and precision medicine for cancer and other medical conditions allowing earlier and more effective treatment.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative technology. Our breath sampling and analysis platforms can spot diseases like cancer earlier than existing tests. This improves survival rates and saves money in the long term. Our goal is to save 100,000 lives and $1.5 billion dollars in healthcare costs globally by 2020” said Billy Boyle, co-founder and CEO at Owlstone Medical. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

 

About Owlstone Medical

( www.owlstonemedical.com )

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, infectious disease and inflammatory disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.

Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, Owlstone Inc is a profitable business selling its proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.

Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.

Further information is available on the Company's website, www.owlstonemedical.com.

 

About Cavendish Global

(www.cavendishglobal.com)

Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation.

For more information: http://cavendishglobal.com

For Further Information, Contact:

Cavendish Global Health Impact Forum
Ian Kenyon
Director, Corporate Communications and Marketing
Ian.Kenyon@CavendishGlobal.com

Owlstone Medical
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730919

Stay informed and receive all the latest updates and news straight into your inbox

Sign up to our newsletter